Ecotest Flu A/B + COVID Rapid Antigen Test Pen
Point of care viral Flu RAT testing made easy
Reliable results in only 15 minutes
The Ecotest Influenza A/B + COVID-19 Rapid Antigen Nasal Test is developed for point of care use. Negative results do not exclude the possibility of COVID-19 or Influenza A/B infection, and government health advice should be followed as well as taking protective measures including social distancing and wearing face masks when administering tests.Speak to sales
Ready for Point of Care use
Easy to use
The only Flu/Covid two-step RAT test on the Australian market makes Flu and COVID testing as simple a quick nasal swab, followed by popping the test pen into the buffer cap. No more messing around with solutions or cassettes. It’s fast, simple and safe.
Up to date with strains
Developed to test for the most current Influenza A/B strains in the Southern hemisphere as well as COVID-19, it’s a simple rapid test that offers a lot of information.
Accurate and reliable
With an impressive 99% accuracy, this fully self-contained testing mechanism is easy to store and administer to even sensitive or young patients, while minimising risk of cross-contamination.
A 3-in-1 test designed for convenience
Ecotest Flu A+B & Covid-19 Tests feature a patented design and are convenient to store, stack or display, as well as easy to use and dispose of. Our flu RAT tests are ideal for government, corporate or private applications, and are available for delivery in custom order quantities of 5 and 20 packs, to suit your distribution needs.Speak to sales
Convenient 3-in-1 Influenza & Covid testing
Designed to be non-invasive and easy to self-administer, the Ecotest Flu A+B & Covid-19 RAT Test Pen’s patented two-step design streamlines the process of testing for common seasonal viruses (SARS-CoV-2, Influenza A, and Influenza B). Test by swabbing your nose, then placing the pen into its buffer cap, and reading results in 15 minutes. No need for extra components, or mixing reagents: it’s as easy as that.
Each 20PK Point of Care test kit includes the following:
- 20 Individually packaged Flu + Covid Rapid Antigen tests in foil wrappers with desiccant
- 1 packaged insert for the Rapid Antigen Test
- 1 positive external control swab
- 1 negative external control swab
- 2 single buffer pouches for external control
- 1 package insert for external control
Biolink can help your business save money and time with our range of rapid antigen tests.
STEP 1. Remove the Flu test protector and insert the nasal collector into a nostril. Rotate the collector 5 times against the nasal wall. Repeat in other nostril.
STEP 2. Place the Flu A/B test device vertically into the tube with the extraction buffer. Ensure the top of the base aligns to the middle of the supporting line.
NOTE: Wait 15 minutes, then check your results flu RAT results. Do not read results after 30 minutes, as they will be invalid.
Results interpretation (COVID)
Two coloured bands appear on the membrane. One band appears in the control region (C) and another band appears in the test region (T).
Body: Only one coloured band appears in the control region (C). No apparent coloured band appears in the test region (T).
Control band fails to appear. Results from any test which has not produced a control band at the specified read time must be discarded.
Results interpretation (Influenza A+B)
One coloured band appears in the control region (C), and another coloured band in region (A).
One coloured band appears in the control region (C), and another coloured band in region (B).
One coloured band appears in the control region (C), and two other coloured bands appear in both region (A) and region (B).
Influenza A+B Negative
Only one coloured band appears in the control region (C), and band appears neither in region (A) nor region (B).
No coloured band appears in the control region (C), whether a test band(s) is present or not. Repeat invalid tests with a new sample, new test device and reagent.
COVID, Influenza A+B test specifications
|Assay format||Lateral flow|
|Testing time||15 minutes to results; maximum 30 minutes|
|Antigen||Nucleocapsid protein (N)|
|Sample material||Nasopharyngeal swab|
|COVID sensitivity||96.0% (92.3%~98.0%)|
|COVID specificity||96.0% (92.3%~98.0%)|
|Influenza A sensitivity||96.1% (90.4%~98.5%)|
|Influenza A specificity||99.5 % (98.5%~99.8%)|
|Influenza B sensitivity||94.0 % (86.8%~97.4%)|
|Influenza B specificity||99.7 % (98.8%~99.9%)|
International supplier of rapid antigen tests to government and multi-industry clients
Access to global supply networks and technologies to support your brand
Rapid & Reliable
Rapid and reliable shipping and logistics to support your network and supply chain
Experts in at-home and point-of-care rapid testing across Europe, Australia, and North America
Straightforward ordering and distribution processes, with 24-hour global support channels
We work with specialists in user-friendly rapid antigen pens and cassettes for various diseases
Instructions for use
Download the comprehensive instructions guide to using the Ecotest Influenza A/B + COVID-19 Antigen Nasal Test.
Download instructions →
Result reference sheet
Download a detailed description of how to read Ecotest Influenza A/B + COVID-19 Antigen Nasal Test results.
Download reference sheet →
Download our product brochure, which includes details and features of the Ecotest Influenza A/B + COVID-19 Antigen Nasal Test.
Download brochure →
Get our Biolink Companion app on the Google Play Store or Apple App Store
Get in touch
Drop us a line. We'll get back to you as soon as we can.
Made for convenience
Our pens are designed to be used in scenarios that don't allow for the easy mixing of reagents or buffer solutions. This makes it ideal for use in locations like schools, workplaces, day-cares, or hospitals, where it may be hard or inconvenient to perform a cassette style test. Just as quick and accurate as other RATs; but an easier, more comfortable user experience.
Summary of use
The Influenza A/B + COVID-19 Antigen Nasal Test Kit is an in-vitro immunoassay intended for the qualitative detection of antigens in nasal swab specimens from patients with COVID-19, and/or Influenza A/B (within first 4 days of symptom onset). This test doesn't discriminate between SARS-coronavirus and SARS-CoV-2 (COVID-19).
Precautions for use
The test is intended for point-of-care use; and not intended for home testing (or self-testing). It obtains a preliminary result only, to aid diagnosis of COVID-19, and Influenza A/B. Please note that negative results do not preclude viral infections—test results should not be the sole basis for treatment or other management decisions.